作者: Max Dahele , Kenneth C. H. Fearon
DOI: 10.1007/978-88-470-0552-5_58
关键词: Cancer 、 Bioinformatics 、 Targeted therapy 、 In vivo 、 Immune system 、 Lung 、 Medicine 、 Cancer cachexia 、 Cachexia 、 Inflammatory response
摘要: Cancer cachexia is a major symptom burden for patients with cancer.Cachexia occurs in up to one half of all diagnosed cancer [1] and more frequent lung upper-gastrointestinal cancer.Cancer results from the interaction host tumour. However, nature this incompletely understood [2] [5], including dynamics response (activation systemic inflammatory response, metabolic, immune neuroendocrine changes) those tumour characteristics or tumour-derived products that influence expression syndrome (e.g. proteolysis-inducing factor [PIF]). The relative importance individual mediators pathways different types unclear, as reason why individuals apparently similar tumours should show considerable variation their tendency develop cachexia.As ability discriminate vivo improves, so too appropriately targeted therapy.